Woessner R - Search Results

1

Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.

Schiller H, Huth F, Schuhler C, Drollmann A, Kaul M, Woessner R, Shah B, Weis W, End P. Schiller H, et al. Among authors: woessner r. Eur J Pharm Sci. 2022 May 1;172:106155. doi: 10.1016/j.ejps.2022.106155. Epub 2022 Mar 3. Eur J Pharm Sci. 2022. PMID: 35247543 Free article.

2

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.

Huth F, Schiller H, Jin Y, Poller B, Schuhler C, Weis W, Woessner R, Drollmann A, End P. Huth F, et al. Among authors: woessner r. Clin Transl Sci. 2022 Jan;15(1):118-129. doi: 10.1111/cts.13126. Epub 2021 Aug 25. Clin Transl Sci. 2022. PMID: 34432364 Free PMC article.

3

Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.

Poller B, Woessner R, Barve A, Tillmann HC, Vemula J, Nica A, Elbast W, Schiller H, End P, Camenisch G, Weiss M. Poller B, et al. Among authors: woessner r. Pulm Pharmacol Ther. 2019 Aug;57:101809. doi: 10.1016/j.pupt.2019.101809. Epub 2019 Jun 10. Pulm Pharmacol Ther. 2019. PMID: 31195091

4

Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.

Pearson D, Weiss HM, Jin Y, Jaap van Lier J, Erpenbeck VJ, Glaenzel U, End P, Woessner R, Eggimann F, Camenisch G. Pearson D, et al. Among authors: woessner r. Drug Metab Dispos. 2017 Jul;45(7):817-825. doi: 10.1124/dmd.117.075358. Epub 2017 Apr 25. Drug Metab Dispos. 2017. PMID: 28442499 Clinical Trial.

5

Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.

Chen J, Stringer R, Shah B, Gu J, Zhang Y, Hackling M, Prince W, Woessner R. Chen J, et al. Among authors: woessner r. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1253-1263. doi: 10.1002/cpdd.1140. Epub 2022 Aug 12. Clin Pharmacol Drug Dev. 2022. PMID: 35962468

6

Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.

Chen J, Gu J, Shah B, Stringer R, Reis da Silva Torrao L, Hackling M, Nidamarthy PK, Prince WT, Woessner R. Chen J, et al. Among authors: woessner r. J Clin Pharmacol. 2022 Apr;62(4):520-531. doi: 10.1002/jcph.1996. Epub 2022 Feb 24. J Clin Pharmacol. 2022. PMID: 34738233

7

CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.

De Buck S, Kucher K, Hara H, Gray C, Woessner R. De Buck S, et al. Among authors: woessner r. Biopharm Drug Dispos. 2018 Sep;39(8):394-402. doi: 10.1002/bdd.2157. Biopharm Drug Dispos. 2018. PMID: 30171694 Clinical Trial.

8

Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.

Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF. Khindri S, et al. Among authors: woessner r. BMC Pulm Med. 2011 May 26;11:31. doi: 10.1186/1471-2466-11-31. BMC Pulm Med. 2011. PMID: 21615886 Free PMC article. Clinical Trial.

9

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.

Bruin G, Hasselberg A, Koroleva I, Milojevic J, Calonder C, Soon R, Woessner R, Pariser DM, Boutouyrie-Dumont B. Bruin G, et al. Among authors: woessner r. Clin Pharmacol Ther. 2019 Dec;106(6):1380-1388. doi: 10.1002/cpt.1558. Epub 2019 Aug 3. Clin Pharmacol Ther. 2019. PMID: 31228872 Free PMC article.

10

Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.

Walles M, Wolf T, Jin Y, Ritzau M, Leuthold LA, Krauser J, Gschwind HP, Carcache D, Kittelmann M, Ocwieja M, Ufer M, Woessner R, Chakraborty A, Swart P. Walles M, et al. Among authors: woessner r. Drug Metab Dispos. 2013 Sep;41(9):1626-41. doi: 10.1124/dmd.112.050716. Epub 2013 Jun 17. Drug Metab Dispos. 2013. PMID: 23775850

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters